제넥신

095700KOSDAQ자연과학 및 공학 연구개발업

55.0 / 100

Reference Date: 2026-04-13

Financial Score25.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Genexine focuses on developing innovative therapies for cancer and immune-related diseases using its proprietary bioPROTAC technology, which leverages biologics like nanobodies to overcome limitations of traditional small-molecule-based PROTAC approaches. The company aims to effectively degrade target proteins by utilizing advanced targeted protein degradation techniques, enabling precise and efficient disease treatment.

Number of Employees

68people

Average Salary

82.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

0.90Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE

-10.71Industry Average -32.113.5Point

Well below industry avg

Debt Ratio

3.10Industry Average 7.526.5Point

Half of industry avg (excellent)

Trend 2023~20254.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.1% (2-year basis)

Operating Profit Growth Rate

2.0 / 3

Avg ▲6.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
'미국 암학회 출격' K바이오…항암 신약 검증 무대 오른다
내달 개막하는 미국 암연구학회 연례학술대회(AACR 2026)에서 국내 제약바이오 기업들이 차세대 항암 파이프라인을 선보이며 기술력을 검증할 예정이라는 내용입니다.

Detailed Momentum

52-week position3.0Point

52w lower range (26%)

Current 4,860Won52-week high 6,59052-week low 4,235

1-month return3.0Point

1m -0.51% (flat)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral정기주주총회결과2026-03-30